



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

028/826 361

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

96200820.7

Der Präsident des Europäischen Patentamts:  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE

05/03/97



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.: 96200820.7  
Application no.:  
Demande n°:

Anmeldetag: 26/03/96  
Date of filing:  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
Akzo Nobel N.V.  
6824 BM Arnhem  
NETHERLANDS

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:  
Estrogen receptor

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:

C12N15/12, C12N15/62, C12N15/85, C07K14/72, C12N1/21, C12N5/16, C12Q1/00, C12Q1/68

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:

The title of the application as originally filed reads as follows :  
Novel estrogen receptor

## Novel estrogen receptor

This invention relates to the field of receptors belonging to the superfamily of nuclear hormone receptors, in particular to steroid receptors. The invention relates to DNA encoding a novel steroid receptor, the preparation of said receptor, the receptor protein, and the uses thereof.

Steroid receptors belong to a superfamily of nuclear hormone receptors involved in ligand-dependent transcriptional control of gene expression. In addition, this superfamily consists of receptors for non-steroid hormones such as vitamine D, thyroid hormones and retinoids (Giguère et al, Nature 330, 624-629, 1987; Evans, R.M., Science 240, 889-895, 1988). Moreover, a range of nuclear receptor-like sequences have been identified which encode so-called 'orphan' receptors: these receptors are structurally related to and therefore classified as nuclear receptors, although no putative ligands have been identified yet (B.W. O'Malley, Endocrinology 125, 1119-1170, 1989; D.J. Mangelsdorf and R.M. Evans, Cell, 83, 841-850, 1995).

The superfamily of nuclear hormone receptors share a modular structure in which six distinct structural and functional domains, A to F, are displayed (Evans, Science 240, 889-895, 1988). A nuclear hormone receptor is characterized by a variable N-terminal region (domain A/B), followed by a centrally located, highly conserved DNA-binding domain (hereinafter referred to as DBD; domain C), a variable hinge region (domain D), a conserved ligand-binding domain (herein after referred to

as LBD; domain E) and a variable C-terminal region (domain F).

The N-terminal region, which is highly variable in size and sequence, is poorly conserved among the different members of the superfamily. This part of the receptor is involved in the modulation of transcription activation (Bocquel et al, Nucl. Acid Res., 17, 2581-2595, 1989; Tora et al, Cell 59, 477-487, 1989).

The DBD consists of approximately 66 to 70 amino acids and is responsible for DNA-binding activity: it targets the receptor to specific DNA sequences called hormone responsive elements (hereinafter referred to as HRE) within the transcription control unit of specific target genes on the chromatin (Martinez and Wahli, In 'Nuclear Hormone Receptors', Acad. Press, 125-153, 1991).

The LBD is located in the C-terminal part of the receptor and is primarily responsible for ligand binding activity. In this way, the LBD is essential for recognition and binding of the hormone ligand and, in addition possesses a transcription activation function, thereby determining the specificity and selectivity of the hormone response of the receptor. Although moderately conserved in structure, the LBD's are known to vary considerably in homology between the individual members of the nuclear hormone receptor superfamily (Evans, Science 240, 889-895, 1988; P.J. Fuller, FASEB J., 5, 3092-3099, 1991; Mangelsdorf et al, Cell, Vol. 83, 835-839, 1995).

Functions present in the N-terminal region, LBD and DBD operate independently from each other and it has been shown that these domains can be exchanged between nuclear receptors (Green et al, Nature, Vol. 325, 75-78, 1987). This results in chimeric nuclear receptors, such as described for instance in WO-A-8905355.

When a hormone ligand for a nuclear receptor enters the cell by diffusion and is recognized by the LBD, it will bind to the specific receptor protein, thereby initiating an allosteric alteration of the receptor protein. As a result of this alteration the ligand/receptor complex switches to a transcriptionally active state and as such is able to bind through the presence of the DBD with high affinity to the corresponding HRE on the chromatin DNA (Martinez and Wahli, 'Nuclear Hormone Receptors', 125-153, Acad. Press, 1991). In this way the ligand/receptor complex modulates expression of the specific target genes. The diversity achieved by this family of receptors results from their ability to respond to different ligands.

The steroid receptors are a distinct class of the nuclear receptor superfamily, characterized in that the putative ligands are steroid hormones. The receptors for glucocorticoids (GR), mineralcorticoids (MR), progesterone (PR), androgens (AR) and estrogens (ER) are classical steroid receptors. Furthermore, the steroid receptors have the unique ability upon activation to bind to palindromic DNA sequences, the so called HRE's, as homodimers. The GR, MR, PR and AR recognize the same DNA sequence, while the ER recognizes a different DNA sequence. (Beato et al, Cell, Vol. 83, 851-857, 1995). After binding to DNA, the steroid receptor is thought to interact with components of the basal transcriptional machinery and with sequence-specific transcription factors, thus modulating the expression of specific target genes.

Several HRE's have been identified, which are responsive to the hormone/receptor complex. These HRE's are situated in the transcriptional control units of the various target genes such as mammalian growth hormone genes (responsive to G, E, T), mammalian prolactin genes and progesterone receptor genes (responsive to E), avian ovalbumin genes (responsive to P), mammalian methallothionein gene (responsive to G) and mammalian hepatic  $\alpha_2\mu$ -globulin gene (responsive to A, E, T, G).

The steroid receptors have been known to be involved in embryonic development, adult homeostasis as well as organ physiology. Various diseases and abnormalities have been ascribed to a disturbance in the steroid hormone pathway. Since the steroid receptors exercise their influence as hormone-activated transcriptional modulators, it can be anticipated that mutations and defects in these receptors, as well as overstimulation or blocking of these receptors might be the underlying reason for the altered pattern. A better knowledge of these receptors, their mechanism of action and of the ligands which bind to said receptor might help to create a better insight in the underlying mechanism of the hormone pathway, which eventually will lead to better treatment of the diseases and abnormalities linked to altered hormone/receptor functioning.

For this reason cDNA's of the steroid and several other nuclear receptors of several mammals, including humans, have been isolated and the corresponding amino acid sequence have been deduced, such as for example the human steroid receptors PR, ER, GR, MR, and AR, the human non-steroid receptors for vitamine D, thyroid hormones, and retinoids such as retinol A and retinoic acid. In

addition, cDNA's well over 100 mammalian orphan receptors have been isolated, for which no putative ligands are known yet (Mangelsdorf et al, Cell, Vol.83, 835-839, 1995). However, there is still a great need for the elucidation of other nuclear receptors, in order to unravel the various roles these receptors play in normal physiology and pathology.

The present invention provides for such a novel nuclear receptor. More specific, the present invention provides for novel steroid receptors, having estrogen mediated activity. Said novel steroid receptors are novel estrogen receptors, which are able to bind and be activated by, for example, estradiol, estrone and estrinol.

According to the present invention it has been found that a novel estrogen receptor is expressed as an 8 kb transcript in human thymus, spleen, peripheral blood lymphocytes (PBLs), ovary and testis. Furthermore, additional transcripts have been identified. In testis, an additional transcript of 1.3 kb was detected. Another transcript of approximately 10 kb was identified in ovary, thymus and spleen. These two transcripts are probably generated by alternative splicing of the gene encoding the novel estrogen receptor according to the invention.

Cloning of the cDNA's encoding the novel estrogen receptors according to the invention revealed that several splicing variants of said receptor can be distinguished. At the protein level, these variants differ only at the C-terminal part.

It is true that an estrogen receptor is already known: cDNA encoding the classical ER was isolated (Green, et al, Nature 320, 134-139, 1986; Greene et al, Science 231, 1150-1154, 1986), and its amino acid sequence deduced.

5 Although both ER's share a great deal of homology, the amino acid sequence of both receptors vary considerably. The homology between the classical ER and the novel ER's according to the invention resides predominantly in the DBD's and LBD's of said receptors. Thus, the two  
10 receptors are distinct, encoded for by different genes, which belong to the subclass of estrogen receptors.

Furthermore, two orphan receptors, ERR $\alpha$  and ERR $\beta$ , having an estrogen receptor related structure have been described. Based on the structural relatedness of ERR $\alpha$   
15 and ERR $\beta$  with the classic ER, these orphans are considered to be members of the estrogen receptors subclass. These receptors, however, have not been reported to be able to bind estrodial or any other hormone that binds to the classic ER, and other ligands  
20 which bind to these receptors have not been found yet (ref?). The novel estrogen receptor according to the invention distinguishes itself clearly from these receptors since it was found to bind estrogens.

The fact that a novel ER according to the invention  
25 has been found is all the more surprising, since any suggestion towards the existence of additional estrogen receptors was absent in the scientific literature: neither the isolation of the classical ER nor the orphan receptors ERR $\alpha$  and ERR $\beta$  suggested or hinted towards the  
30 presence of additional estrogen receptors such as the receptors according to the invention. The identification of additional ER's could be a major step forward for the existing clinical therapies, which are based on the presence of one ER and as such ascribe all estrogen



mediated abnormalities and/or diseases to this one receptor. The presence of additional estrogen receptors, such as the receptors according to the invention will be useful in the development of hormone analogs that  
5 selectively activate either the classic ER or the novel estrogen receptor according to the invention. This should be considered as one of the major advantages of the present invention.

10 Thus, in one aspect, the present invention provides for isolated cDNA encoding a novel steroid receptor. In particular, the present invention provides for isolated cDNA encoding a novel estrogen receptor.

15 According to this aspect of the present invention, there is provided an isolated DNA encoding a steroid receptor protein having an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said DNA-binding domain of said  
20 receptor protein exhibits at least 80% homology with the amino acid sequence shown in SEQ ID NO:3, and the amino acid sequence of said ligand-binding domain of said receptor protein exhibits at least 70% homology with the amino acid sequence shown in SEQ ID NO:4.

25 In particular, the isolated DNA encodes a steroid receptor protein having an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said DNA-binding domain of said receptor protein exhibits at least 90%, preferably 95%, more preferably 98%, most preferably 100% homology with  
30 the amino acid sequence shown in SEQ ID NO:3.

More particularly, the isolated DNA encodes a steroid receptor protein having an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said ligand-binding domain of said

receptor protein exhibits at least 75%, preferably 80%, more preferably 90%, most preferably 100% homology with the amino acid sequence shown in SEQ ID NO:4.

5 A preferred isolated DNA according to the invention encodes a steroid receptor protein having the amino acid sequence shown in SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:21.

10 A more preferred isolated DNA according to the invention is an isolated DNA comprising a nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:20.

The DNA according to the invention may be obtained from cDNA. Alternatively, the coding sequence might be genomic DNA, or prepared using DNA synthesis techniques.

15 The DNA according to the invention will be very useful for in vivo expression of the novel receptor proteins according to the invention in sufficient quantities and in substantially pure form.

20 In another aspect of the invention, there is provided for a steroid receptor comprising the amino acid sequence encoded by the above described DNA molecules.

25 The steroid receptor according to the invention has an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said DNA-binding domain of said receptor exhibits at least 80% homology with the amino acid sequence shown in SEQ ID NO:3, and the amino acid sequence of said ligand-binding domain of said receptor exhibits at least 70% homology with the amino acid sequence shown in SEQ ID NO:4.

30 In particular, the steroid receptor according to the invention has an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid

sequence of said DNA-binding domain of said receptor exhibits at least 90%, preferably 95%, more preferably 98%, most preferably 100% homology with the amino acid sequence shown in SEQ ID NO:3.

5       More particular, the steroid receptor according to the invention has an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said ligand-binding domain of said receptor exhibits at least 75%, preferably 80%, more preferably  
10       90%, most preferably 100% homology with the amino acid sequence shown in SEQ ID NO:4.

It will be clear for those skilled in the art that also steroid receptor proteins comprising combined DBD and LBD preferences and DNA encoding such receptors are  
15       subject of the invention.

Preferably, the steroid receptor according to the invention comprises an amino acid sequence shown in SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:21.

Also within the scope of the present invention are  
20       steroid receptor proteins which comprise variations in the amino acid sequence of the DBD and LBD without losing their respective DNA-binding or ligand-binding activities. The variations that can occur in those amino acid sequence comprise deletions, substitutions,  
25       insertions, inversions or additions of (an) amino acid(s) in said sequence, said variations resulting in amino acid difference(s) in the overall sequence. It is well known in the art of proteins and peptides that these amino acid differences lead to amino acid sequences that are  
30       different from, but still homologous with the native amino acid sequence they have been derived from..

Amino acid substitutions that are expected not to essentially alter biological and immunological activities, have been described in for example Dayhof,

M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3. Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val. Based on this information Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science 227, 1435-1441, 1985) and determining the functional similarity between homologous polypeptides.

Variations in amino acid sequence of the DBD according to the invention resulting in an amino acid sequence that has at least 80% homology with the sequence of SEQ ID NO:3 will lead to receptors still having sufficient DNA binding activity. Variations in amino acid sequence of the LBD according to the invention resulting in an amino acid sequence that has at least 70% homology with the sequence of SEQ ID NO:4 will lead to receptors still having sufficient ligand binding activity.

Homology as defined herein is expressed in percentages, determined via PCGENE.

Comparing the amino acid sequence of the classic ER and the ER's according to the invention revealed a high degree of similarity within their respective DBD's. The conservation of the P-box (amino acids E-G-X-X-A) which is responsible for the actual interactions of ER $\alpha$  with the target DNA element (Zilliacus et al., Mol.Endo. 9, 389, 1995; Glass, End.Rev. 15, 391, 1994), is indicative for a recognition of estrogen responsive elements (ERE's) by the ER's according to the invention. Therefore, the classical ER and novel ER's according to the invention may have overlapping target gene specificities. This

could indicate that in tissues which co-express both  
respective ER's, these receptors compete for ERE's. The  
er's according to the invention may regulate  
transcription of target genes differently from classical  
ER regulation or could simply block classical ER  
functioning by occupying estrogen responsive elements.

Thus, a preferred steroid receptor according to the  
invention comprises the amino acid sequence E-G-X-X-A  
within the P box of the DNA binding domain, wherein X  
stands for any amino acid. Also within the scope of the  
invention is isolated DNA encoding such a receptor.

Methods to prepare the receptors according to the  
invention are well known in the art (Sambrook et al.,  
Molecular Cloning: a Laboratory Manual, Cold Spring  
Harbor Laboratory Press, Cold Spring Harbor, latest  
edition). The most practical approach is to produce these  
receptors by expression of the DNA encoding the desired  
protein.

A wide variety of host cell and cloning vehicle  
combinations may be usefully employed in cloning the  
nucleic acid sequence coding for the receptor of the  
invention. For example, useful cloning vehicles may  
include chromosomal, non-chromosomal and synthetic DNA  
sequences such as various known bacterial plasmids and  
wider host range plasmids and vectors derived from  
combinations of plasmids and phage or virus DNA. Useful  
hosts may include bacterial hosts, yeasts and other  
fungi, plant or animal hosts, such as Chinese Hamster  
Ovary (CHO) cells or monkey cells and other hosts.

Vehicles for use in expression of the ligand-binding  
domain of the present invention will further comprise  
control sequences operably linked to the nucleic acid

sequence coding for the ligand-binding domain. Such control sequences generally comprise a promoter sequence and sequences which regulate and/or enhance expression levels. Furthermore an origin of replication and/or a dominant selection marker are often present in such vehicles. Of course control and other sequences can vary depending on the host cell selected.

Techniques for transforming or transfecting host cells are quite known in the art (see, for instance, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982 and 1989).

Recombinant expression vectors comprising the DNA of the invention as well as cells transformed with said DNA or said expression vector also form part of the present invention.

In a further aspect of the invention, there is provided for a chimeric receptor protein having an N-terminal domain, a DNA-binding domain, and a ligand-binding domain, characterized in that at least one of the domains originates from a receptor protein according to the invention, and at least one of the other domains of said chimeric protein originates from another receptor protein from the nuclear receptor superfamily, provided that the DNA-binding domain and the ligand-binding domain of said chimeric receptor protein originate from different proteins.

In particular, the chimeric receptor according to the invention comprises the LBD according to the invention, said LBD having an amino acid sequence which exhibits at least 70% homology with the amino acid sequence shown in SEQ ID NO:4. In that case the N-terminal domain and DBD should be derived from another nuclear receptor, such as

for example PR. In this way a chimeric receptor is constructed which is activated by a ligand of the ER according to the invention and which targets a gene under control of a progesterone responsive element. The  
5 chimeric receptors having a LBD according to the invention are useful for the screening of compounds to identify novel ligands or hormone analogs which are able to activate an ER according to the invention.

In addition, chimeric receptors comprising a DBD  
10 according to the invention, said DBD having an amino acid sequence exhibiting at least 80% homology with the amino acid sequence shown in SEQ ID NO:3, and a LBD and, optionally, an N-terminal domain derived from another nuclear receptor, can be successfully used to identify  
15 novel ligands or hormone analogs for said nuclear receptors. Such chimeric receptors are especially useful for the identification of the respective ligands of orphan receptors.

Since steroid receptors have three domains with  
20 different functions, which are more or less independent, it is possible that all three functional domains have been derived from different members of the steroid receptor superfamily.

Molecules which contain parts having a different  
25 origin are called chimeric. Such a chimeric receptor comprising the ligand-binding domain and/or the DNA-binding domain of the invention may be produced by chemical linkage, but most preferably the coupling is accomplished at the DNA level with standard molecular  
30 biological methods by fusing the nucleic acid sequences encoding the necessary steroid receptor domains. Hence, DNA encoding the chimeric receptor proteins according to the invention are also subject of the present invention.

Such chimeric proteins can be prepared by transfecting DNA encoding these chimeric receptor proteins to suitable host cells and culturing these cells under suitable conditions.

5

It is extremely practical if, next to the information for the expression of the steroid receptor, also the host cell is transformed or transfected with a vector which carries the information for a reporter molecule. Such a vector coding for a reporter molecule is characterized by having a promoter sequence containing one or more hormone responsive elements (HRE) functionally linked to an operative reporter gene. Such a HRE is the DNA target of the activated steroid receptor and, as a consequence, it enhances the transcription of the DNA coding for the reporter molecule. In *in vivo* settings of steroid receptors the reporter molecule comprises the cellular response to the stimulation of the ligand. However, it is possible *in vitro* to combine the ligand-binding domain of a receptor to the DNA binding domain and transcription activating domain of other steroid receptors, thereby enabling the use of other HRE and reporter molecule systems. One such a system is established by a HRE presented in the MMTV-LTR (mouse mammary tumor virus long terminal repeat sequence in connection with a reporter molecule like the firefly luciferase gene or the bacterial gene for CAT (chloramphenicol transferase). Other HRE's which can be used are the rat oxytocin promotor, the retinoic acid responsive element, the thyroid hormone responsive element, the estrogen responsive element and also synthetic responsive elements have been described (for instance in Fuller, *ibid.* page 3096). As reporter molecules next to CAT and luciferase  $\beta$ -galactosidase can be used.

10

15

20

25

30



Steroid receptors and chimeric receptors according to the present invention can be used for the *in vitro* identification of novel ligands or hormonal analogs. For this purpose binding studies can be performed with cells transformed with DNA according to the invention or an expression vector comprising DNA according to the invention, said cells expressing the steroid receptors or chimeric receptors according to the invention.

The novel steroid receptor and chimeric receptors according to the invention as well as the ligand-binding domain of the invention, can be used in an assay for the identification of functional ligands or hormone analogs for the nuclear receptors.

Thus, the present invention provides for a method for identifying functional ligands for the steroid receptors and chimeric receptors according to the invention, said method comprising the steps of

- a) introducing into a suitable host cell 1) DNA or an expression vector according to the invention, and 2) a suitable reporter gene functionally linked to an operative hormone response element, said HRE being able to be activated by the DNA-binding domain of the receptor protein encoded by said DNA;
- b) bringing the host cell from step a) into contact with potential ligands which will possibly bind to the ligand-binding domain of the receptor protein encoded by said DNA from step a);

- c) monitoring the expression of the receptor protein encoded by said reporter gene of step a).

If expression of the reporter gene is induced with respect to basic expression (without ligand), the functional ligand can be considered as an agonist; if expression of the reporter gene remains unchanged or is reduced with respect to basic expression, the functional ligand can be a suitable (partial) antagonist.

For performing such kind of investigations host cells which have been transformed or transfected with both a vector encoding a functional steroid receptor and a vector having the information for a hormone responsive element and a connected reporter molecule are cultured in a suitable medium. After addition of a suitable ligand, which will activate the receptor the production of the reporter molecule will be enhanced, which production simply can be determined by assays having a sensitivity for the reporter molecule. See for instance WO-A-8803168. Assays with known steroid receptors have been described (for instance S. Tsai et al., Cell 57, 443, 1989; M. Meyer et al., Cell 57, 433, 1989).

## Legends to the figures

### Figure 1.

Northern analysis of the novel estrogen receptor. Two different multiple tissue Northern blots (Clontech) were hybridised with a specific probe for the novel estrogen receptor (see examples). Indicated are the human tissues the RNA originated from and the position of the size markers in kilobases (kb).

**Figure 2.**

Histogram showing the 3- to 4-fold stimulatory effect of ethinyl-estradiol, estriol and estrone on the luciferase activity mediated by the novel estrogen receptor. An expression vector encoding the novel estrogen receptor was transiently transfected into CHO cells together with a reporter construct containing the rat oxytocin promoter in front of the firefly luciferase encoding sequence (see examples).

**Examples**

**A. Molecular cloning of the novel estrogen receptor.**

Two degenerate oligonucleotides containing inosines (I) were based on conserved regions of the DNA-binding domains and the ligand-binding domains of the human steroid hormone receptors.

**Primer**

5'-GGIGA(C/T)GA(A/G)GC(A/T)TCIGGITG(C/T)CA(C/T)TA(C/T)TA(C/T)GG-3' (SEQ ID NO:7).

**Primer**

5'-AAGCCTGG(C/G)A(C/T)IC(G/T)(C/T)TTIGCCCAI(C/T)TIAT-3' (SEQ ID NO:8).

As template, cDNA from human EBV-stimulated PBLs (peripheral blood leukocytes) was used. One microgram of total RNA was reverse transcribed in a 20 µl reaction containing 50 mM KCl, 10 mM Tris-HCl pH 8.3, 4 mM MgCl<sub>2</sub>, 1 mM dNTPs (Pharmacia), 100 pmol random hexanucleotides (Pharmacia), 30 Units Rnase inhibitor (Pharmacia) and 200

Units M-MLV Reverse transcriptase (Gibco BRL). Reaction mixtures were incubated at 37°C for 30 minutes and heat-inactivated at 100°C for 5 minutes. The cDNA obtained was used in a 100 µl PCR reaction containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin (w/v), 3% DMSO, 1 microgram of primer #1 and primer #2 and 2.5 Units of Amplitaq DNA polymerase (Perkin Elmer). PCR reactions were performed in the Perkin Elmer 9600 thermal cycler. The initial denaturation (4 minutes at 94°C) was followed by 36 cycles with the following conditions: 30 sec. 94°C, 30 sec. 45°C, 1 minute 72°C and after 7 minutes at 72°C the reactions were stored at 4°C. Aliquots of these reactions were analysed on a 1.5% agarose gel. Fragments of interest were cut out of the gel, reamplified using identical PCR-conditions and purified using Qiaex II (Qiagen). Fragments were cloned in the PCRII vector and transformed into bacteria using the TA-cloning kit (Invitrogen). Plasmid DNA was isolated for nucleotide sequence analysis using the Qiagen plasmid midi protocol (Qiagen). Nucleotide sequence analysis was performed with the ALF automatic sequencer (Pharmacia) using a T7 DNA sequencing kit (Pharmacia) with vector-specific or fragment-specific primers.

One cloned fragment corresponded to a novel estrogen receptor (ER) which is closely related to the classical estrogen receptor. Part of the cloned novel estrogen receptor fragment (nucleotides 466 to 797 in SEQ ID 1) was amplified by PCR using oligonucleotide #3 TGTTACGAAGTGGGAATGGTGA (SEQ ID NO:9) and oligonucleotide #2 and used as a probe to screen a human testis cDNA library in λgt11 (Clontech #HL1010b). Recombinant phages were plated (using Y1090 bacteria grown in LB medium supplemented with 0.2% maltose) at a density of 40.000

per 135 mm dish and replica filters (Hybond-N, Amersham) were made as described by the supplier. Filters were prehybridised in a solution containing 0.5 M phosphate buffer (pH 7.5) and 7% SDS at 65°C for at least 30 minutes. DNA probes were purified with Qiaex II (Qiagen), <sup>32</sup>P-labeled with a Decaprime kit (Ambion) and added to the prehybridisation solution. Filters were hybridised at 65°C overnight and then washed in 0.5 X SSC/0.1% SDS at 65°C. Two positive plaques were identified and could be shown to be identical. These clones were purified by rescreening one more time. A PCR reaction on the phage eluates with the  $\lambda$ gt11-specific primers #4: 5'-TTGACACCAGACCAACTGGTAATG-3' (SEQ ID NO:10) and #5: 5'-GGTGGCGACGACTCCTGGAGCCCG-3' (SEQ ID NO:11) yielded a fragment of 1700 basepairs on both clones. Subsequent PCR reactions using combinations of a gene-specific primer #6: 5'-GTACACTGATTGTAGCTGGAC-3' (SEQ ID NO:12) with the  $\lambda$ gt11 primer #4 and gene-specific primer #7: 5'-CCATGATGATGTCCTGACC-3' (SEQ ID NO:13) with  $\lambda$ gt11 primer #5 yielded fragments of 450 bp and 1000 bp, respectively, which were cloned in the PCR II vector and used for nucleotide sequence analysis. The conditions for these PCR reactions were as described above except for the primer concentrations (200 ng of each primer) and the annealing temperature (60°C). Since in the cDNA clone the homology with the ER is lost abruptly at a site which corresponds to the exon 7/exon 8 boundary in the ER, it was suggested that this sequence corresponds to intron 7 of the novel ER gene. For verification of the nucleotide sequences of this cDNA clone, a 1200 bp fragment was generated on the cDNA clone with  $\lambda$ gt11 primer #4 with a gene-specific primer #8 corresponding to the 3' end of

exon 7: 5'-TCGCATGCCTGACGTGGGAC-3' (SEQ ID NO:14) using the proofreading Pfu polymerase (Stratagene). This fragment was also cloned in the PCRII vector and completely sequenced and was shown to be identical to the sequences obtained earlier.

To obtain nucleotide sequences of the novel ER downstream of exon 7, a degenerate oligonucleotide based on the AF-2 region of the classic ER (#9: 5'-GGC(C/G)TCCAGCATCTCCAG(C/G)A(A/G)CAG-3'; SEQ ID NO:15) was used together with the gene-specific oligonucleotide #10: 5'-GGAAGCTGGCTCACTTGCTG-3' (SEQ ID NO:16) using testis cDNA as template (Marathon ready testis cDNA, Clontech Cat #7414-1). A specific 220 bp fragment corresponding to nucleotides 1112 to 1332 in SEQ ID No. 1 was cloned and sequenced and was shown to contain high homology with the corresponding region in the classic ER. In order to obtain sequences of the novel ER downstream of the AF-2 region, RACE (rapid amplification of cDNA ends) PCR reactions were performed using the Marathon-ready testis cDNA (Clontech) as template. The initial PCR was performed using oligonucleotide #11: 5'-TCTTGTCTGGACAGGGATG-3' (SEQ ID NO:17) in combination with the AP1 primer provided in the kit. A nested PCR was performed on an aliquot of this reaction using oligonucleotide #10 in combination with the oligo dT primer provided in the kit. Subsequently, an aliquot of this reaction was used in a nested PCR using oligonucleotide #12: 5'-GCATGGAACATCTGCTCAAC-3' (SEQ ID NO:18) in combination with the oligo dT primer. Nucleotide sequence analysis of a specific fragment that was obtained (corresponding to nucleotides 1256 to 1431 in SEQ ID NO 1) revealed a sequence encoding the carboxyterminus of the novel ER ligand-binding domain, including an F-domain and a translational stopcodon.

*B. Identification of two splice variants of the novel estrogen receptor.*

5        Rescreening of the testis cDNA library with a probe  
corresponding to nucleotides 917 to 1248 in SEQ ID No. 1  
yielded two hybridizing clones, the 3' end of which were  
amplified by PCR (gene-specific primer #8: 5'-  
GGAAGCTGGCTCACTTGCTG-3' together with primer #4), cloned  
and sequenced. One clone was shown to contain an  
10       alternative exon 8 (exon 8B) of the novel ER. As a  
consequence of the introduction of this exon through a  
specific alternative splicing reaction, the reading frame  
encoding the novel ER is immediately terminated, thereby  
creating a truncation of the carboxyterminus of the novel  
15       ER.

Screening of a human thymus cDNA library (Clontech  
HL1074a) with the probe corresponding to nucleotides 935  
to 1266 in SEQ ID No. 1, revealed another splice variant.  
The 3' end of one hybridizing clone was amplified using  
20       primer #8 with the  $\lambda$ gt10-specific primer #13 5'-  
AGCAAGTTCAGCCTGTTAAGT-3' (SEQ ID NO:19), cloned in the  
PCRII vector and sequenced. The obtained nucleotide  
sequence upstream of the exon 7/exon 8 boundary were  
identical to the clones identified earlier. However, an  
25       alternative exon 8 (exon 8C) was present at the 3' end  
encoding two C-terminal amino acids followed by a stop-  
codon.

30       These two variants of the novel estrogen receptor do  
not contain the AF-2 region and therefore probably lack  
the ability to modulate transcription of target genes in  
a ligand-dependent fashion. However, the variants  
potentially could interfere with the functioning of the

wild-type classic ER and/or the wild-type novel ER, either by heterodimerization or by occupying estrogen response elements. A mutant of the classic ER (ER1-530) has been described which closely resembles the two variants of the novel estrogen receptor described above. ER1-530 has been shown to behave as a dominant-negative receptor i.e. it can block the intracellular activity of the wild type ER (Ince et al, J. Biol. Chem. 268, 14026-14032, 1993).

#### ***C. Northern blot analysis.***

Human multiple tissue Northern blots (MTN-blots) were purchased from Clontech and prehybridized for at least 1 hour at 65°C in 0.5 M phosphate buffer pH 7.5 with 7% SDS. DNA fragments that were used as probes were 32P-labeled using a labelling kit (Ambion), denatured by boiling and added to the prehybridisation solution. Washing conditions were: 3X SSC at room temperature, followed by 3 X SSC at 65°C, and finally 1 X SSC at 65°C. The filters were then exposed to X-ray films for one week. Two transcripts of approximately 8 kb and 10 kb were detected in thymus, spleen, ovary and testis. In addition, a 1.3 kb transcript is detected in testis.

#### ***D. Ligand-dependent transcription activation by the novel estrogen receptor protein.***

##### **Cell culture**

Chinese Hamster Ovary (CHO K1) cells were obtained from ATCC (CCL61) and maintained at 37°C in a humidified atmosphere (5% CO<sub>2</sub>) as a monolayer culture in fenolred-free M505 medium. The latter medium consists of a mixture



(1:1) of Dulbecco's Modified Eagle's Medium (DMEM, Gibco 074-200) and Nutrient Medium F12 (Ham's F12, Gibco 074-1700) supplemented with 2.5 mg/ml sodium carbonate (Baker), 55 µg/ml sodium pyruvate (Fluka), 2.3 µg/ml β-mercaptoethanol (Baker), 1.2 µg/ml ethanolamine (Baker), 360 µg/ml L-glutamine (Merck), 0.45 µg/ml sodium selenite (Fluka), 62.5 µg/ml penicillin (Mycopharm), 62.5 µg/ml streptomycin (Serva), and 5% charcoal-treated bovine calf serum (Hyclone).

#### Recombinant vectors

The novel ER encoding sequence as presented in SEQ ID No 1 was amplified by PCR using oligonucleotides 5'-CTTGGATCCATAGCCCTGCTGTGATGAATTACAG-3' (SEQ ID NO:22) (underlined is the translation initiation codon) and : 5'-GATGGATCCTCACCTCAGGGCCAGGCGTCACTG-3' (SEQ ID NO:23) (underlined is the translation stopcodon, antisense). The resulting BamH1 fragment (approximately 1450 base pairs) was then cloned in the mammalian cell expression vector pNGV1 behind the SV40 early promoter. In addition, this vector contains the IgG and Mulv enhancers.

The reporter expression vector was based on the rat oxytocin gene regulatory region (position -363/+16 as a HindIII/ MboI fragment; R.Ivell, and D.Richter, Proc.Natl.Acad.Sci.USA 81, 2006-2010, 1984) linked to the firefly luciferase encoding sequence; the regulatory region of the oxytocin gene were shown to possess functional estrogen hormone response elements in vitro for both the rat (R.Adan, N.Walther, J.Cox, R.Ivell, and P.Burbach, Biochem.Biophys.Res.Comm. 175, 117-122, 1991) and the human (S.Richard, and H.Zingg, J.Biol.Chem. 265, 6098-6103, 1990).

#### Transient transfection

1 x 10<sup>5</sup> CHO cells were seeded in 6-wells Nunclon tissue culture plates and DNA was introduced by use of lipofectin (Gibco BRL). Hereto, the DNA (1 µg of both receptor and reporter vector in 250 µL Optimem, Gibco BRL) was mixed with an equal volume of lipofectin reagent (7 µL in 250 µL Optimem, Gibco) and allowed to stand at room temperature for 15 min. After washing the cells twice with serum-free medium (M505) new medium (500 µL Optimem, Gibco) was added to the cells followed by the dropwise addition of the DNA-lipofectin mixture. After incubation for a 5 hour period at 37°C cells were washed twice with fenolred-free M505 + 5% charcoal-treated bovine calf serum and incubated overnight at 37°C. After 24 hours hormone (ethinyl-estradiol, etriol or estron) was added to the medium (100 nmol/L). Cell extracts were made 48 hours posttransfection by the addition of 200 µL lysisbuffer (0.1 M phosphate buffer pH7.8, 0.2% Triton X-100). After incubation for 5 min at 37°C the cell suspension was centrifuged (Eppendorf centrifuge, 5 min) and 20 µL sample was added to 50 µL luciferase assay reagent (Promega). Light emission was measured in a luminometer (Berthold Biolumat) for 10 sec at 562 nm.

### Results.

CHO cells transiently transfected with the novel ER expression vector and a reporter plasmid showed a 3 to 4 fold increase in luciferase activity in respons to ethinyl-estradiol as compared to untreated cells. A similar transactivation was obtained upon treatment with estriol and estrone. The results indicate not only that the novel ER can bind estrogen hormones but also that the ligand-activated receptor can bind to the ERE within the

rat oxytocin promoter and activate transcription of the luciferase reporter gene.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Akzo nobel n.v.
- (B) STREET: Velperweg 76
- (C) CITY: Arnhem
- (E) COUNTRY: The Netherlands
- (F) POSTAL CODE (ZIP): 6824 BM
- (G) TELEPHONE: 0412-666379
- (H) TELEFAX: 0412-650592
- (I) TELEX: 37503 akpha nl

(ii) TITLE OF INVENTION: Novel estrogen receptor

(iii) NUMBER OF SEQUENCES: 23

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1434 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGAATTACA GCATTCCCAG CAATGTEACT AACTTGGAAG GTGGGCCTGG TCGGCAGACC  
60

5 ACAAGCCCAA ATGTGTTGTG GCCAACACCT GGGCACCTTT CTCCTTTAGT GGTCCATCGC  
120

CAGTTATCAC ATCTGTATGC GGAACCTCAA AAGAGTCCCT GGTGTGAAGC AAGATCGCTA  
180

10 GAACACACCT TACCTGTAAA CAGAGAGACA CTGAAAAGGA AGGTTAGTGG GAACCGTTGC  
240

GCCAGCCCTG TTA CTGTTCC AGGTTCAAAG AGGGATGCTC ACTTCTGCGC TGTCTGCAGC  
300

15 GATTACGCAT CGGGATATCA CTATGGAGTC TGGTCGTGTG AAGGATGTAA GGCCTTTTTT  
360

20 AAAAGAAGCA TTCAAGGACA TAATGATTAT ATTTGTCCAG CTACAAATCA GTGTACAATC  
420

GATAAAAACC GCGCAAGAG CTGCCAGGCC TGCCGACTTC GGAAGTGTTA CGAAGTGGGA  
480

25 ATGGTGAAGT GTGGCTCCCG GAGAGAGAGA TGTGGGTACC GCCTTGTGCG GAGACAGAGA  
540

AGTGCCGACG AGCAGCTGCA CTGTGCCGGC AAGGCCAAGA GAAGTGGCGG CCACGCGCCC  
600

30 CGASTGCGGG AGCTGCTGCT GGACGCCCTG AGCCCCGAGC AGCTAGTGCT CACCCTCCTG  
660

GAGGCTGAGC CGCCCCATGT GCTGATCAGC CGCCCCAGTG CGCCCTTCAC CGAGGCCTCC  
720

35 ATGATGATGT CCTGACCAA GTTGGCCGAC AAGGAGTTGG TACACATGAT CAGCTGGGCC  
780

40 AAGAAGATTC CCGGCTTTGT GGAGCTCAGC CTGTTGACC AAGTGCGGCT CTTGGAGAGC  
840

TGTTGGATGG AGGTGTTAAT GATGGGGCTG ATGTGGCGCT CAATTGACCA CCGGGCAAG  
900

45

CTCATCTTTG CTCCAGATCT TGTTCCTGGAC AGGGATGAGG GGAAATGCCG AGAAGGAATT  
960

5 CTGGAAATCT TTGACATGCT CCTGGCAACT ACTTCAAGGT TTCGAGAGTT AAAACTCCAA  
1020

CACAAAGAAT ATCTCTGTGT CAAGGCCATG ATCCTGCTCA ATTCCAGTAT GTACCCCTCTG  
1080

10 GTCACAGCGA CCCAGGATGC TGACAGCAGC CGGAAGCTGG CTCACTTGCT GAACGCCGTG  
1140

15 ACCGATGCTT TGGTTTGGGT GATTGCCAAG AGCGGCATCT CCTCCCAGCA GCAATCCATG  
1200

CGCCTGGCTA ACCTCCTGAT GTCCTGTCC CACGTCAGGC ATGCGAGTAA CAAGGGCATG  
1260

20 GAACATCTGC TCAACATGAA GTGCAAAAAT GTGGTCCCAG TGTATGACCT GCTGCTGGAG  
1320

ATGCTGAATG CCCACGTGCT TCGCGGGTGC AAGTCCTCCA TCACGGGGTC CGAGTGCAGC  
1380

25 CCGGCAGAGG ACAGTAAAAG CAAAGAGGGC TCCCAGAACC CACAGTCTCA GTGA  
1434

(2) INFORMATION FOR SEQ ID NO: 2:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1251 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATGAATTACA GCATTCCGAG CAATGTCAC T AACTTGAAG GTGGGCTCG TCGGCAGACC  
60

5 ACAAGCCCAA ATGTGTTGTG GCCAACACCT GGGCACCTTT CTCCTTTAGT GGTCCATCGC  
120

CAGTTATCAC ATCTGTATGC GGAACCTCAA AAGAGTCCCT GGTGTGAAGC AAGATCGCTA  
180

10 GAACACACCT TACCTGTAAA CAGAGAGACA CTGAAAAGGA AGGTTAGTGG GAACCGTTGC  
240

GCCAGCCCTG TTA CTGGTCC AGGTTCAAAG AGGGATGCTC ACTTCTGCGC TGTCTGCAGC  
300

15 GATTACGCAT CGGGATATCA CTATGGAGTC TGGTCGTGTG AAGGATGTAA GGCCTTTTTT  
360

20 AAAAGAAGCA TTCAAGGACA TAATGATTAT ATTTGTCCAG CTACAAATCA GTGTACAATC  
420

GATAAAAACC GCGCAAGAG CTGCCAGGCC TGCCGACTTC GGAAGTGTTA CGAAGTGGGA  
480

25 ATGGTGAAGT GTGGCTCCCG GAGAGAGAGA TGTGGGTACC GCCTGTGCG GAGACAGAGA  
540

AGTGCCGACG AGCAGCTGCA CTGTGCCGGC AAGGCCAAGA GAAGTGGCGG CCACGCGCCC  
600

30 CGAGTGGGG AGCTGCTGCT GGACGCCCTG AGCCCCGAGC AGCTAGTGCT CACCCTCCTG  
660

GAGGCTGAGC CGCCCCATGT GCTGATCAGC CGCCCCAGT CGCCCTTCAC CGAGGCTCTC  
720

35 ATGATGATGT CCTGACCAA GTTGGCCGAC AAGGAGTTGG TACACATGAT CAGCTGGGCC  
780

40 AAGAAGATTC CCGGCTTTGT GGAGCTCAGC CTGTTGACC AAGTGGCGCT CTTGGAGAGC  
840

TGTTGGATGG AGGTGTTAAT GATGGGGCTG ATGTGGCGCT CAATTGACCA CCCC GGCAAG  
900

45

- 30 -

CTCATCTTTG CTCCAGATCT TGTTCCTGGAC AGGGATGAGG GGAAATGCGT AGAAGGAATT  
960

5 CTGGAAATCT TTGACATGCT CCTGGCAACT ACTTCAAGGT TTCGAGAGTT AAAACTCCAA  
1020

CACAAAGAAT ATCTCTGTGT CAAGGCCATG ATCCTGCTCA ATTCCAGTAT GTACCCCTCTG  
1080

10 GTCACAGCGA CCCAGGATGC TGACAGCAGC CGGAAGCTGG CTCACTTGCT GAACGCCGTG  
1140

ACCGATGCTT TGGTTTGGGT GATTGCCAAG AGCGGCATCT CCTCCCAGCA GCAATCCATG  
1200

15 CGCCTGGCTA ACCTCCTGAT GCTCCTGTCC CACGTCAGGC ATGCGAGGTG A  
1251

(2) INFORMATION FOR SEQ ID NO: 3:

20

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 66 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Cys Ala Val Cys Ser Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp  
1 5 10 15

35

Ser Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His  
20 25 30

Asn Asp Tyr Ile Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn  
35 40 45

40



Gly Met

§

65

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 233 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: peptide

(X1) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20

Leu Val Leu Thr Leu Leu Glu Ala Glu Pro Pro His Val Leu Ile Ser  
1                   5                   10                   15

Arg Pro Ser Ala Pro Phe Thr Glu Ala Ser Met Met Met Ser Leu Thr

25

20

25

30

Lys Leu Ala Asp Lys Glu Leu Val His Met Ile Ser Trp Ala Lys Lys  
35 40 45

30

Ile Pro Gly Phe Val Glu Leu Ser Leu Phe Asp Gln Val Arg Leu Leu  
50 55 60

Glu Ser Cys Trp Met Glu Val Leu Met Met Gly Leu Met Trp Arg Ser  
65 70 75 80

35

Ile Asp His Pro Gly Lys Leu Ile Phe Ala Pro Asp Leu Val Leu Asp  
85 90 95

Arg Asp Glu Gly Lys Cys Val Glu Gly Ile Leu Glu Ile Phe Asp Met

	100	105	110
	Leu Leu Ala Thr Thr Ser Arg Phe Arg Glu Leu Lys Leu Gln His Lys		
	115	120	125
5	Glu Tyr Leu Cys Val Lys Ala Met Ile Leu Leu Asn Ser Ser Met Tyr		
	130	135	140
	Pro Leu Val Thr Ala Thr Gln Asp Ala Asp Ser Ser Arg Lys Leu Ala		
10	145	150	155 160
	His Leu Leu Asn Ala Val Thr Asp Ala Leu Val Trp Val Ile Ala Lys		
	165	170	175
15	Ser Gly Ile Ser Ser Gln Gln Gln Ser Met Arg Leu Ala Asn Leu Leu		
	180	185	190
	Met Leu Leu Ser His Val Arg His Ala Ser Asn Lys Gly Met Glu His		
	195	200	205
20	Leu Leu Asn Met Lys Cys Lys Asn Val Val Pro Val Tyr Asp Leu Leu		
	210	215	220
	Leu Glu Met Leu Asn Ala His Val Leu		
25	225	230	

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 477 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

3

	Ala Leu Ser Pro Glu Gln Leu Val Leu Thr Leu Leu Glu Ala Glu Pro	210	215	220
5	Pro His Val Leu Ile Ser Arg Pro Ser Ala Pro Phe Thr Glu Ala Ser	225	230	235 240
	Met Met Met Ser Leu Thr Lys Leu Ala Asp Lys Glu Leu Val His Met	245	250	255
10	Ile Ser Trp Ala Lys Lys Ile Pro Gly Phe Val Glu Leu Ser Leu Phe	260	265	270
	Asp Gln Val Arg Leu Leu Glu Ser Cys Trp Met Glu Val Leu Met Met	275	280	285
15	Gly Leu Met Trp Arg Ser Ile Asp His Pro Gly Lys Leu Ile Phe Ala	290	295	300
20	Pro Asp Leu Val Leu Asp Arg Asp Glu Gly Lys Cys Val Glu Gly Ile	305	310	315 320
	Leu Glu Ile Phe Asp Met Leu Leu Ala Thr Thr Ser Arg Phe Arg Glu	325	330	335
25	Leu Lys Leu Gln His Lys Glu Tyr Leu Cys Val Lys Ala Met Ile Leu	340	345	350
	Leu Asn Ser Ser Met Tyr Pro Leu Val Thr Ala Thr Gln Asp Ala Asp	355	360	365
30	Ser Ser Arg Lys Leu Ala His Leu Leu Asn Ala Val Thr Asp Ala Leu	370	375	380
35	Val Trp Val Ile Ala Lys Ser Gly Ile Ser Ser Gln Gln Gln Ser Met	385	390	395 400
	Arg Leu Ala Asn Leu Leu Met Leu Leu Ser His Val Arg His Ala Ser	405	410	415

- 35 -

Asn Lys Gly Met Glu His Leu Leu Asn Met Lys Cys Lys Asn Val Val  
 420 425 430

5 Pro Val Tyr Asp Leu Leu Leu Glu Met Leu Asn Ala His Val Leu Arg  
 435 440 445

Gly Cys Lys Ser Ser Ile Thr Gly Ser Glu Cys Ser Pro Ala Glu Asp  
 450 455 460

10

Ser Lys Ser Lys Glu Gly Ser Gln Asn Pro Gln Ser Gln  
 465 470 475

(2) INFORMATION FOR SEQ ID NO: 6:

15

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 416 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

20

(ii) MOLECULE TYPE: protein

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Asn Tyr Ser Ile Pro Ser Asn Val Thr Asn Leu Glu Gly Gly Pro  
 1 5 10 15

30

Gly Arg Gln Thr Thr Ser Pro Asn Val Leu Trp Pro Thr Pro Gly His  
 20 25 30

Leu Ser Pro Leu Val Val His Arg Gln Leu Ser His Leu Tyr Ala Glu  
 35 40 45

35

Pro Gln Lys Ser Pro Trp Cys Glu Ala Arg Ser Leu Glu His Thr Leu  
 50 55 60

	Pro Val Asn Arg Glu Thr Leu Lys Arg Lys Val Ser Gly Asn Arg Cys	
	65	80
5	Ala Ser Pro Val Thr Gly Pro Gly Ser Lys Arg Asp Ala His Phe Cys	
	85	95
	Ala Val Cys Ser Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp Ser	
	100	110
10	Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His Asn	
	115	125
	Asp Tyr Ile Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg	
	130	140
15	Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly	
	145	160
	Met Val Lys Cys Gly Ser Arg Arg Glu Arg Cys Gly Tyr Arg Leu Val	
	165	175
	Arg Arg Gln Arg Ser Ala Asp Glu Gln Leu His Cys Ala Gly Lys Ala	
	180	190
25	Lys Arg Ser Gly Gly His Ala Pro Arg Val Arg Glu Leu Leu Leu Asp	
	195	205
	Ala Leu Ser Pro Glu Gln Leu Val Leu Thr Leu Leu Glu Ala Glu Pro	
	210	220
30	Pro His Val Leu Ile Ser Arg Pro Ser Ala Pro Phe Thr Glu Ala Ser	
	225	240
	Met Met Met Ser Leu Thr Lys Leu Ala Asp Lys Glu Leu Val His Met	
	245	255
35	Ile Ser Trp Ala Lys Lys Ile Pro Gly Phe Val Glu Leu Ser Leu Phe	
	260	270

	Asp Gln Val Arg Leu Leu Glu Ser Cys Trp Met Glu Val Leu Met Met	
	275	280 285
5	Gly Leu Met Trp Arg Ser Ile Asp His Pro Gly Lys Leu Ile Phe Ala	
	290	295 300
	Pro Asp Leu Val Leu Asp Arg Asp Glu Gly Lys Cys Val Glu Gly Ile	
	305	310 315 320
10	Leu Glu Ile Phe Asp Met Leu Leu Ala Thr Thr Ser Arg Phe Arg Glu	
	325	330 335
	Leu Lys Leu Gln His Lys Glu Tyr Leu Cys Val Lys Ala Met Ile Leu	
	340	345 350
15	Leu Asn Ser Ser Met Tyr Pro Leu Val Thr Ala Thr Gln Asp Ala Asp	
	355	360 365
	Ser Ser Arg Lys Leu Ala His Leu Leu Asn Ala Val Thr Asp Ala Leu	
20	370	375 380
	Val Trp Val Ile Ala Lys Ser Gly Ile Ser Ser Gln Gln Gln Ser Met	
	385	390 395 400
25	Arg Leu Ala Asn Leu Leu Met Leu Leu Ser His Val Arg His Ala Arg	
	405	410 415

(2) INFORMATION FOR SEQ ID NO: 7:

30

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: unknown

35

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGIGAYGARG CWTGIGGITG YCAYTAYGG  
29

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AAGCCTGGSA YICKYTTIGC CCAIYTIAT  
29

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TGTTACGAAG TGGGAATGGT GA  
22



(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TTGACACCAG ACCAACTGGT AATG  
24

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGTGGCGACG ACTCCTGGAG CCCG  
24

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

10

GTACACTGAT TTGTAGCTGG AC  
22

(2) INFORMATION FOR SEQ ID NO: 13:

15

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: cDNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCATGATGAT GTCCCTGACC  
20

30

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

TCGCATGCCT GACGTGGGAC  
20

5

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGCSTCCAGC ATCTCCAGSA RCAG  
24

20

(2) INFORMATION FOR SEQ ID NO: 16:

25

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGAAGCTGGC TCACTTGCTG  
20

40

(2) INFORMATION FOR SEQ ID NO: 17:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

TCTTGTCTG GACAGGGATG  
20

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCATGAACA TCTGCTCAAC  
20

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGCAAGTTCA GCCTGTTAAG T  
21

10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 1257 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

25

ATGAATTACA GCATTCCCAG CAATGTCAC TAACTTGGGAG GTGGGCCTGG TCGGCAGACC  
60

30

ACAAGCCCAA ATGTGTTGTG GCCAACACCT GGGCACCTTT CTCCTTTAGT GGTCCATCGC  
120

CAGTTATCAC ATCTGTATGC GGAACCTCAA AAGAGTCCCT GGTGTGAAGC AAGATCGCTA  
180

35

GAACACACCT TACCTGTAAA CAGAGAGACA CTGAAAAGGA AGGTTAGTGG GAACCCGTTC  
240

GCCAGCCCTG TTAAGTGTCC AGGTTCAAAG AGGGATGCTC AATTCTGCGC TGTCTGCAGC  
300

40

GATTACGCAT CGGGATATCA CTATGGAGTC TGGTCGTGTG AAGGATGTAA GGCCTTTTTT  
360

AAAAGAAGCA TTCAAGGACA TAATGATTAT ATTTGTCCAG CTACAAATCA GTGTACAATC  
420

5 GATAAAAACC GCGCAAGAG CTGCCAGGCC TGCCGACTTC GGAAGTGTTA CGAAGTGGGA  
480

ATGGTGAAGT GGGCTCCCG GAGAGAGAGA TGTGGGTACC GCCTTGTTCG GAGACAGAGA  
540

10 AGTGCCGACG AGCAGCTGCA CTGTGCCGGC AAGGCCAAGA GAAGTGGCGG CCACGCGCCC  
600

CGASTGCGGG AGCTGCTGCT GGACGCCCTG AGCCCCGAGC AGCTAGTGCT CACCCTCCTG  
660

15 GAGGCTGAGC CGCCCCATGT GCTGATCAGC CCCCCAGTG CGCCCTTCAC CGAGGCTTCC  
720

20 ATGATGATGT CCTGACCAA GTTGGCCGAC AAGGAGTTGG TACACATGAT CAGCTGGGCC  
780

AAGAAGATTC CCGCCTTTGT GGAGCTCAGC CTGTTGACC AAGTGGCGCT CTTGGAGAGC  
840

25 TGTGGATGG AGGTGTTAAT GATGGGGCTG ATGTGGCGCT CAATTGACCA CCCCAGCAAG  
900

CTCATCTTTC CTCCAGATCT TCTTCTGGAC AGGGATGAGG GGAAATGCGT AGAAGGAATT  
960

30 CTGGAAATCT TTGACATGCT CCTGGCAACT ACTTCAAGGT TTCGAGAGTT AAAACTCCAA  
1020

35 CACAAAGAAT ATCTCTGTGT CAAGGCCATG ATCCTGCTCA ATTCCAGTAT GTACCCTCTG  
1080

GTCACAGCGA CCCAGGATGC TGACAGCAGC CGGAAGCTGG CTCACCTTCT GAACGCCGTG  
1140

40 ACCGATGCTT TGGTTTGGGT GATTGCCAAG AGCGGCATCT CCTCCAGCA GCAATCCATG  
1200

CGCCTGGCTA ACCTCCTGAT GCTCCTGTCC CACGTCAGGC ATGCGAGGTC TGCCTGA  
1257

45

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 418 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

15 Met Asn Tyr Ser Ile Pro Ser Asn Val Thr Asn Leu Glu Gly Gly Pro  
1 5 10 15

Gly Arg Gln Thr Thr Ser Pro Asn Val Leu Trp Pro Thr Pro Gly His  
20 20 25 30

Leu Ser Pro Leu Val Val His Arg Gln Leu Ser His Leu Tyr Ala Glu  
35 40 45

Pro Gln Lys Ser Pro Trp Cys Glu Ala Arg Ser Leu Glu His Thr Leu  
25 50 55 60

Pro Val Asn Arg Glu Thr Leu Lys Arg Lys Val Ser Gly Asn Arg Cys  
65 70 75 80

30 Ala Ser Pro Val Thr Gly Pro Gly Ser Lys Arg Asp Ala His Phe Cys  
85 90 95

Ala Val Cys Ser Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp Ser  
100 105 110

35 Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His Asn  
115 120 125

Asp Tyr Ile Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg

	130	135	140
	Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly		
	145	150	155 160
5	Met Val Lys Cys Gly Ser Arg Arg Glu Arg Cys Gly Tyr Arg Leu Val		
	165	170	175
	Arg Arg Gln Arg Ser Ala Asp Glu Gln Leu His Cys Ala Gly Lys Ala		
10	180	185	190
	Lys Arg Ser Gly Gly His Ala Pro Arg Val Arg Glu Leu Leu Leu Asp		
	195	200	205
15	Ala Leu Ser Pro Glu Gln Leu Val Leu Thr Leu Leu Glu Ala Glu Pro		
	210	215	220
	Pro His Val Leu Ile Ser Arg Pro Ser Ala Pro Phe Thr Glu Ala Ser		
20	225	230	235 240
	Met Met Met Ser Leu Thr Lys Leu Ala Asp Lys Glu Leu Val His Met		
	245	250	255
	Ile Ser Trp Ala Lys Lys Ile Pro Gly Phe Val Glu Leu Ser Leu Phe		
25	260	265	270
	Asp Gln Val Arg Leu Leu Glu Ser Cys Trp Met Glu Val Leu Met Met		
	275	280	285
30	Gly Leu Met Trp Arg Ser Ile Asp His Pro Gly Lys Leu Ile Phe Ala		
	290	295	300
	Pro Asp Leu Val Leu Asp Arg Asp Glu Gly Lys Cys Val Glu Gly Ile		
35	305	310	315 320
	Leu Glu Ile Phe Asp Met Leu Leu Ala Thr Thr Ser Arg Phe Arg Glu		
	325	330	335
	Leu Lys Leu Gln His Lys Glu Tyr Leu Cys Val Lys Ala Met Ile Leu		



	340	345	350
	Leu Asn Ser Ser Met Tyr Pro Leu Val Thr Ala Thr Gln Asp Ala Asp		
	355	360	365
5	Ser Ser Arg Lys Leu Ala His Leu Leu Asn Ala Val Thr Asp Ala Leu		
	370	375	380
	Val Trp Val Ile Ala Lys Ser Gly Ile Ser Ser Gln Gln Gln Ser Met		
10	385	390	395 400
	Arg Leu Ala Asn Leu Leu Met Leu Leu Ser His Val Arg His Ala Arg		
	405	410	415
15	Ser Ala		

(2) INFORMATION FOR SEQ ID NO: 22:

- 20 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 34 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CTTGGATCCA TAGCCCTGCT GTGATGAATT ACAG  
34

35 (2) INFORMATION FOR SEQ ID NO: 23:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

10

GATGGATCCT CACCTCAGGG CCAGGCCTCA CTG  
33

Claims:

1. Isolated DNA encoding a protein having an N-terminal domain, a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said DNA-binding domain of said protein exhibits at least 80% homology with the amino acid sequence shown in SEQ ID NO:3, and the amino acid sequence of said ligand-binding domain of said protein exhibits at least 70% homology with the amino acid sequence shown in SEQ ID NO:4.
2. Isolated DNA according to claims 1, characterized in that the amino acid sequence of said DNA-binding domain of said protein exhibits at least 90%, preferably 95%, more preferably 98%, most preferably 100% homology with the amino acid sequence shown in SEQ ID NO:3.
3. Isolated DNA according to claims 1 or 2, characterized in that the amino acid sequence of said ligand-binding domain of said protein exhibits at least 75%, preferably 80%, more preferably 90%, most preferably 100% homology with the amino acid sequence shown in SEQ ID NO:4.
4. Isolated DNA according to claims 1 to 3, said DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:21.
5. Isolated DNA according to claims 1 to 4, characterized in that said DNA comprises the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID

NO:20.

6. A recombinant expression vector comprising the DNA according to any of the claims 1 to 5.
7. A cell transfected with DNA according to claims 1 to 5 or an expression vector according to claim 6.
8. A cell according to claim 7 which is a stable transfected cell line which expresses the steroid receptor protein according to any of the claims 9 to 11.
9. Protein encoded by DNA according to claims 1 to 5 or an expression vector according to claim 6.
10. Protein according to claim 9, said protein comprising the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:21.
11. Chimeric protein having an N-terminal domain, a DNA-binding domain, and a ligand-binding domain, characterized in that at least one of said domains of said chimeric protein originates from a protein according to claims 9 or 10, and at least one of the other domains of said chimeric protein originates from another receptor protein from the nuclear receptor superfamily, provided that the DNA-binding domain and the ligand-binding domain of said chimeric protein originates from different proteins.
12. DNA encoding a protein according to claim 11.

13. Use of a DNA according to claims 1 to 5 or 12, an expression vector according to claim 6, a cell according to claim 7 or 8 or a protein according to claim 9 to 11 in a screening assay for identification of new drugs.
14. A method for identifying functional ligands for the protein according to claims 9 to 11, said method comprising the steps of
- a) introducing into a suitable host cell 1) DNA according to claims 1 to 5 or 12, and 2) a suitable reporter gene functionally linked to an operative hormone response element, said HRE being able to be activated by the DNA-binding domain of the protein encoded by said DNA;
  - b) bringing the host cell from step a) into contact with potential ligands which will possibly bind to the ligand-binding domain of the protein encoded by said DNA from step a);
  - c) monitoring the expression of the protein encoded by said reporter gene of step a).




FIG. 1




Fig. 2

**ABSTRACT**

s The present invention relates to isolated DNA encoding novel estrogen receptors, the proteins encoded by said DNA, chimeric receptors comprising parts of said novel receptors and uses thereof.